Capricor Therapeutics (CAPR) Tops Q2 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Playboy to buy back 16.6M shares from Fortress at $1.05 each
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins